NASDAQ:SRDX

Surmodics Competitors

$38.12

+0.91 (+2.45 %)

(As of 11/23/2020 12:00 AM ET)

Add

Compare

Today's Range

$36.98

Now: $38.12▼

$38.32

50-Day Range

$35.18

MA: $39.13▼

$43.09

52-Week Range

$22.06

Now: $38.12▼

$49.00

Volume41,859 shs

Average Volume66,916 shs

Market Capitalization$518.66 million

P/E Ratio68.07

Dividend YieldN/A

Beta0.98

Surmodics (NASDAQ:SRDX) Vs. ABT, MDT, SYK, ISRG, BDX, and EW

Should you be buying SRDX stock or one of its competitors? Companies in the sub-industry of "health care equipment" are considered alternatives and competitors to Surmodics, including Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), and Edwards Lifesciences (EW).

Surmodics vs. Abbott Laboratories Stock

Abbott Laboratories (NYSE:ABT) and Surmodics (NASDAQ:SRDX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings and profitability.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Abbott Laboratories and Surmodics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abbott Laboratories	1	4	13	0	2.67
Surmodics	0	0	3	0	3.00

Abbott Laboratories presently has a consensus price target of $115.3750, suggesting a potential upside of 5.59%. Surmodics has a consensus price target of $66.6667, suggesting a potential upside of 74.89%. Given Surmodics' stronger consensus rating and higher probable upside, analysts plainly believe Surmodics is more favorable than Abbott Laboratories.

Risk and Volatility

Abbott Laboratories has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, Surmodics has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500.

Insider and Institutional Ownership

63.9% of Abbott Laboratories shares are held by institutional investors. Comparatively, 89.8% of Surmodics shares are held by institutional investors. 1.7% of Abbott Laboratories shares are held by company insiders. Comparatively, 7.7% of Surmodics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Abbott Laboratories and Surmodics' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abbott Laboratories	$31.90 billion	6.07	$3.69 billion	$3.24	33.73
Surmodics	$100.08 million	5.18	$7.59 million	$0.72	52.94

Abbott Laboratories has higher revenue and earnings than Surmodics. Abbott Laboratories is trading at a lower price-to-earnings ratio than Surmodics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Abbott Laboratories and Surmodics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Abbott Laboratories	10.50%	18.19%	8.29%
Surmodics	7.39%	7.49%	5.90%

Summary

Abbott Laboratories beats Surmodics on 8 of the 14 factors compared between the two stocks.

Surmodics vs. Medtronic Stock

Medtronic (NYSE:MDT) and Surmodics (NASDAQ:SRDX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings and profitability.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Medtronic and Surmodics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medtronic	1	3	20	1	2.84
Surmodics	0	0	3	0	3.00

Medtronic presently has a consensus price target of $118.1538, suggesting a potential upside of 6.47%. Surmodics has a consensus price target of $66.6667, suggesting a potential upside of 74.89%. Given Surmodics' stronger consensus rating and higher probable upside, analysts plainly believe Surmodics is more favorable than Medtronic.

Risk and Volatility

Medtronic has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, Surmodics has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500.

Insider and Institutional Ownership

79.9% of Medtronic shares are held by institutional investors. Comparatively, 89.8% of Surmodics shares are held by institutional investors. 0.5% of Medtronic shares are held by company insiders. Comparatively, 7.7% of Surmodics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Medtronic and Surmodics' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medtronic	$28.91 billion	5.16	$4.79 billion	$4.59	24.18
Surmodics	$100.08 million	5.18	$7.59 million	$0.72	52.94

Medtronic has higher revenue and earnings than Surmodics. Medtronic is trading at a lower price-to-earnings ratio than Surmodics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Medtronic and Surmodics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Medtronic	15.80%	10.47%	5.80%
Surmodics	7.39%	7.49%	5.90%

Summary

Surmodics beats Medtronic on 8 of the 15 factors compared between the two stocks.

Surmodics vs. Stryker Stock

Stryker (NYSE:SYK) and Surmodics (NASDAQ:SRDX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings and profitability.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Stryker and Surmodics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stryker	2	9	15	1	2.56
Surmodics	0	0	3	0	3.00

Stryker presently has a consensus price target of $221.44, suggesting a potential downside of 4.97%. Surmodics has a consensus price target of $66.6667, suggesting a potential upside of 74.89%. Given Surmodics' stronger consensus rating and higher probable upside, analysts plainly believe Surmodics is more favorable than Stryker.

Risk and Volatility

Stryker has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500. Comparatively, Surmodics has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500.

Insider and Institutional Ownership

71.0% of Stryker shares are held by institutional investors. Comparatively, 89.8% of Surmodics shares are held by institutional investors. 6.8% of Stryker shares are held by company insiders. Comparatively, 7.7% of Surmodics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Stryker and Surmodics' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stryker	$14.88 billion	5.88	$2.08 billion	$8.26	28.21
Surmodics	$100.08 million	5.18	$7.59 million	$0.72	52.94

Stryker has higher revenue and earnings than Surmodics. Stryker is trading at a lower price-to-earnings ratio than Surmodics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Stryker and Surmodics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Stryker	11.38%	20.53%	8.89%
Surmodics	7.39%	7.49%	5.90%

Summary

Stryker beats Surmodics on 9 of the 15 factors compared between the two stocks.

Surmodics vs. Intuitive Surgical Stock

Intuitive Surgical (NASDAQ:ISRG) and Surmodics (NASDAQ:SRDX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings and profitability.

Earnings and Valuation

This table compares Intuitive Surgical and Surmodics' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intuitive Surgical	$4.48 billion	18.87	$1.38 billion	$9.95	72.27
Surmodics	$100.08 million	5.18	$7.59 million	$0.72	52.94

Intuitive Surgical has higher revenue and earnings than Surmodics. Surmodics is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Intuitive Surgical has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, Surmodics has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500.

Profitability

This table compares Intuitive Surgical and Surmodics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Intuitive Surgical	24.45%	12.08%	10.44%
Surmodics	7.39%	7.49%	5.90%

Insider and Institutional Ownership

86.9% of Intuitive Surgical shares are held by institutional investors. Comparatively, 89.8% of Surmodics shares are held by institutional investors. 1.6% of Intuitive Surgical shares are held by company insiders. Comparatively, 7.7% of Surmodics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Intuitive Surgical and Surmodics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intuitive Surgical	3	7	12	0	2.41
Surmodics	0	0	3	0	3.00

Intuitive Surgical presently has a consensus price target of $718.2778, suggesting a potential downside of 0.11%. Surmodics has a consensus price target of $66.6667, suggesting a potential upside of 74.89%. Given Surmodics' stronger consensus rating and higher probable upside, analysts plainly believe Surmodics is more favorable than Intuitive Surgical.

Summary

Intuitive Surgical beats Surmodics on 9 of the 14 factors compared between the two stocks.

Surmodics vs. Becton, Dickinson and Stock

Becton, Dickinson and (NYSE:BDX) and Surmodics (NASDAQ:SRDX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations and dividends.

Valuation & Earnings

This table compares Becton, Dickinson and and Surmodics' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Becton, Dickinson and	$17.12 billion	3.87	$874 million	$10.20	22.40
Surmodics	$100.08 million	5.18	$7.59 million	$0.72	52.94

Becton, Dickinson and has higher revenue and earnings than Surmodics. Becton, Dickinson and is trading at a lower price-to-earnings ratio than Surmodics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Becton, Dickinson and has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, Surmodics has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500.

Profitability

This table compares Becton, Dickinson and and Surmodics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Becton, Dickinson and	5.11%	13.30%	5.60%
Surmodics	7.39%	7.49%	5.90%

Insider and Institutional Ownership

74.4% of Becton, Dickinson and shares are held by institutional investors. Comparatively, 89.8% of Surmodics shares are held by institutional investors. 0.1% of Becton, Dickinson and shares are held by insiders. Comparatively, 7.7% of Surmodics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings for Becton, Dickinson and and Surmodics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Becton, Dickinson and	0	7	7	1	2.60
Surmodics	0	0	3	0	3.00

Becton, Dickinson and currently has a consensus target price of $280.2857, suggesting a potential upside of 22.67%. Surmodics has a consensus target price of $66.6667, suggesting a potential upside of 74.89%. Given Surmodics' stronger consensus rating and higher possible upside, analysts plainly believe Surmodics is more favorable than Becton, Dickinson and.

Summary

Surmodics beats Becton, Dickinson and on 8 of the 15 factors compared between the two stocks.

Surmodics vs. Edwards Lifesciences Stock

Edwards Lifesciences (NYSE:EW) and Surmodics (NASDAQ:SRDX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations and dividends.

Valuation & Earnings

This table compares Edwards Lifesciences and Surmodics' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edwards Lifesciences	$4.35 billion	12.14	$1.05 billion	$1.86	45.54
Surmodics	$100.08 million	5.18	$7.59 million	$0.72	52.94

Edwards Lifesciences has higher revenue and earnings than Surmodics. Edwards Lifesciences is trading at a lower price-to-earnings ratio than Surmodics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Edwards Lifesciences has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Comparatively, Surmodics has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500.

Profitability

This table compares Edwards Lifesciences and Surmodics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Edwards Lifesciences	18.18%	29.00%	18.10%
Surmodics	7.39%	7.49%	5.90%

Insider and Institutional Ownership

79.7% of Edwards Lifesciences shares are held by institutional investors. Comparatively, 89.8% of Surmodics shares are held by institutional investors. 1.5% of Edwards Lifesciences shares are held by insiders. Comparatively, 7.7% of Surmodics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings for Edwards Lifesciences and Surmodics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edwards Lifesciences	2	5	13	0	2.55
Surmodics	0	0	3	0	3.00

Edwards Lifesciences currently has a consensus target price of $87.7222, suggesting a potential upside of 3.57%. Surmodics has a consensus target price of $66.6667, suggesting a potential upside of 74.89%. Given Surmodics' stronger consensus rating and higher possible upside, analysts plainly believe Surmodics is more favorable than Edwards Lifesciences.

Summary

Edwards Lifesciences beats Surmodics on 8 of the 14 factors compared between the two stocks.